9M deaths caused by drug resistance
An estimated 9 million people per year die of cancer due to drug resistance acquired by tumors against the original drug targets.
Cancer-targeting immune cells loaded with oncolytic viruses
Bioeclipse is developing next generation immunotherapies which utilizes cancer-targeting immune cells loaded with oncolytic viruses, generating a multi-pronged attack on hard-to-treat tumors.
USD 53B market
In the initial basket trial, Bioeclipse Therapeutics is targeting a range of solid tumors with a combined global market size greater than $53 billion.
"CRX100 addresses a significant unmet medical need in fatal conditions for which there are limited treatment options. CRX100, which migrates to the tumor site, targets tumor cells and delivers the cancer-destroying virus, has the potential to significantly help those with chemotherapy-resistant or refractory solid tumors"
Oliver Dorigo M.D., PhD (Director of the Gynecologic Cancer Service at Stanford University)
Get in touch
Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.